Dario L. Goldfarb, Stefan Harrer, et al.
Proceedings of SPIE - The International Society for Optical Engineering 2010
Artificial intelligence (AI) is certainly not a panacea for solving the 'Pharma Dilemma', in which the cost of producing new drugs continues to spiral. However, AI can be used to fundamentally change the way we perform essential steps in clinical trial design and execution, from cohort selection to patient monitoring. Merging AI and clinical expertise across engineering and medical disciplines to explore the impact of these changes on trial performance and success rates is one of the most promising leads we have for restoring efficiency and sustainability to the drug development cycle.
Dario L. Goldfarb, Stefan Harrer, et al.
Proceedings of SPIE - The International Society for Optical Engineering 2010
Stefan Harrer, Pratik Shah, et al.
Trends in Pharmacological Sciences
Subhrajit Roy, Isabell Kiral, et al.
EBioMedicine
David O. S. Melville, Alan E. Rosenbluth, et al.
SPIE Advanced Lithography 2009